![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
Following the large companies in the Major Pharmaceutical Preparations sector, a few overlooked entities are publishing their results. Nuvation Bio Inc told it has reported operating deficit of $-29.338 millions, for the third quarter of 2022.
The operating deficit has deteriorated from $-22.791 millions, from the third quarter of 2021. But more importantly, the market participants are guessing, when the Nuvation Bio Inc s' may start to cite the revenue.
The crucial verdict in financial third quarter of 2022, additionally to the absence of revenue, has been a $-27.203 millions net deficit, as it has intensified notably from $-21.979 millions, relative to the comparable period a year ago.
Nuvation Bio Inc is expected to report next financial recent numbers on February 27, 2023.